Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

INTRODUCTION: Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates pemetrexed (Pem) cytotoxicity in argininosuccinate synthetase 1 (ASS1)–deficient malignant pleural mesothelioma (MPM). We conducted a phase 1 dose-expansion study at the recommended phase 2 dose of ADI-PEG 20 with Pem an...

Descripción completa

Detalles Bibliográficos
Autores principales: Szlosarek, Peter W., Phillips, Melissa M., Pavlyk, Iuliia, Steele, Jeremy, Shamash, Jonathan, Spicer, James, Kumar, Sanjeev, Pacey, Simon, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John, Moir, Graeme, Lau, Kelvin, Ellis, Stephen, Sheaff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474273/
https://www.ncbi.nlm.nih.gov/pubmed/34589965
http://dx.doi.org/10.1016/j.jtocrr.2020.100093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474273/
https://www.ncbi.nlm.nih.gov/pubmed/34589965
http://dx.doi.org/10.1016/j.jtocrr.2020.100093

Ejemplares similares